JAZZ
Jazz Pharmaceuticals plc
Halal Rating :
Last Price
$121.26
Last updated:
Market Cap
-
7D Change
-1.54%
1 Year Change
1.19%
Company Overview
Industries
Exchange
Next Earnings Date
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases with limited or no treatment options. The company's key therapeutic areas include sleep disorders, oncology, and rare diseases. Their portfolio includes products like Xywav and Xyrem for narcolepsy, Zepzelca for small cell lung cancer, and Rylaze for acute lymphoblastic leukemia.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.05b | $794.76m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $1.02b | $824.38m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $901.98m | $835.78m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Jazz Pharmaceuticals plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.